Considering the fact that CD5+ DLBCL shows many aggressive clinical features 8, frequent central nervous system relapse 9, and poor prognosis 9, we speculated that some of these proteins might be useful as biomarkers for more detailed identification of the aggressive subgroups for DLBCL including CD5+ DLBCL. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.